📰 Valuating News
Page 18 - Valuating News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Valuating. Real-time updates on events, politics, business and more.
October 25, 2021
Data presented by Professor Christophe Le Tourneau at the 2021 Annual Meeting of the American Society for Radiation Oncology First survival data from Phase I Dose Expansion in tough-to-treat elderly
October 14, 2021
Trial is designed to advance pelareorep's clinical development in China, the world's second-largest pharmaceutical market SAN DIEGO and CALGARY, AB, Oct. 14, 2021 /PRNewswire/ -- Oncolytics
October 13, 2021
THR-687 is a potent pan-RGD integrin antagonist holding potential as a next generation first line therapy for DME, currently a $4.5 billion market opportunity THR-687 also holds promise for treatment
October 12, 2021
DJ Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting Arix Bioscience
October 11, 2021
The European Unions drug regulator said it was evaluating a marketing authorisation for an antibody cocktail developed by Roche and Regeneron for treatment and prevention of COVID-19 in people above... | October 11, 2021
October 6, 2021
Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, announces that it has dosed the first patients in its Phase I/II clinical study of CAM-H2 for
October 2, 2021
Treatment with ruxolitinib cream (Opzelura) resulted in facial repigmentation at Week 24, characterized by a significant proportion of patients achieving =75% improvement from baseline in the facial
September 30, 2021
Decision taken to move the highest dose of THR-149 (0.13mg) into Part B of the study based on favorable safety profile and positive efficacy data Oxurion is moving into Part B of study evaluating THR-149
September 30, 2021
On 16 September 2021, the Court of Arbitration for Sport (CAS) handed down its Award in CAS 2021/A/7579 & 7580, dismissing the appeals of the World Anti-Doping Agency (WADA) and Sport Integrity Austr
September 17, 2021
- Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 - - Data support the use of toripalimab with chemotherapy as first-line therapy for